Navigation Links
Genomas Clinical Study Finds Increased Prevalence of Drug Metabolism Deficiencies in Patients With Serious Psychotropic Side Effects
Date:12/9/2008

Data Support Case for DNA-Guided Medicine in Psychiatry

HARTFORD, Conn., Dec. 9 /PRNewswire/ -- Results from a clinical study published in the current issue of the Future Medicine Group (London) journal Personalized Medicine (Vol. 5, No. 6, pp. 579-587, 2008) are helping to point the way toward the application of DNA-guided medicine to predict psychotropic side effects. The study was conducted at The Institute of Living of Hartford Hospital in collaboration with Genomas.

The CYP2C9, CYP2C19 and CYP2D6 genes from the cytochrome P450 family were chosen for DNA typing because their common variants result in deficient metabolic capacity for many psychotropic drugs. Combinatorial gene analysis revealed that 57 percent of individuals in the psychiatric population were carriers of multiple gene variations associated with no or poor drug metabolism capacity on 2 or 3 genes compared to 36 percent of individuals in the control population. Individuals that are multiply deficient in CYP450 metabolic routes are at risk for developing serious side effects to a variety of psychotropic medications.

"We found clear evidence that there were significantly more innate drug metabolism deficiencies based on the gene variants predominantly observed in the population experiencing side effects," said Gualberto Ruano, M.D., Ph.D., President and CEO of Genomas, and Director of Genetics Research, Hartford Hospital. "Our goal is to enhance patient safety by preventing predictable side effects and at the same time build the case for DNA typing in the optimized utilization of health care resources. We are integrating this clinical experience with development of our PhyzioType Systems for DNA-Guided Medicine."

ABOUT GENOMAS

Genomas(R) Inc. is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company develops revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs in cardiovascular and psychiatric medicine. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. www.genomas.net


'/>"/>
SOURCE Genomas Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... India , January 24, 2017 ... titled, "Cold Chain Logistics Market by Application Type (Fruits ... Meat, Fish & Sea Food, Drugs & Pharmaceuticals, and ... projects that the global cold chain logistics market is ... a CAGR of 16% (2016 to 2022). ...
(Date:1/24/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and ... finalists in the Regeneron Science Talent Search, the nation,s ... high school seniors. Finalists were selected based on the ... The finalists will now go to ... undergo a rigorous judging process to determine the top ...
(Date:1/24/2017)... 24, 2017 Research and Markets has announced ... Trends - Product, Material - Forecast to 2025" report to ... ... a CAGR of around 5.4% over the next decade to reach ... trends that the market is witnessing include 3D medical printing is ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... ... and eliminate cyber threats in real-time, today announced a strategic partnership with ... customers to monitor, respond and protect their critical information assets and infrastructure, in ...
(Date:1/24/2017)... ... 24, 2017 , ... His message has been heard by more than 100,000 ... Distracted Driving , Joel Feldman, has reached his biggest national audience yet: the three ... the top newspapers in circulation in the country, and he hopes it will help ...
(Date:1/24/2017)... ... ... Saturday, January 28, the BCFA presents more than 20 local performances including Chinese music, ... Zhou, Mara McClain & Sarah Nordlund Dennis. Local chefs and restaurants provide a taste ... games, crafts & more. Festivities begin at 11:00 am and end at 2:30 pm. ...
(Date:1/24/2017)... ... January 24, 2017 , ... Inspiration, Community ... Well-meaning studies such as the Fordham Institute’s High Stakes for High Achievers ... such as including gifted or high-achieving students as a subgroup and reporting their ...
(Date:1/24/2017)... ... January 24, 2017 , ... Date aired: January ... Sharon Kleyne, the nation’s foremost water advocate and host of the nationally syndicated ... on Voice America, once again welcomed one of her favorite guests and colleagues, ...
Breaking Medicine News(10 mins):